Efavirenz: a review
SME Vrouenraets, FWNM Wit, J Tongeren… - Expert opinion on …, 2007 - Taylor & Francis
Efavirenz is a non-nucleoside reverse transcriptase inhibitor that in most treatment
guidelines is recommended to be taken combined with two nucleoside analogue reverse …
guidelines is recommended to be taken combined with two nucleoside analogue reverse …
[PDF][PDF] Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment
JM Llibre, B Clotet - Aids Rev, 2012 - researchgate.net
Once-daily single-tablet regimens represent the paramount simplification of antiretroviral
treatment achieved so far. They include drugs with favorable pharmacokinetics that allow …
treatment achieved so far. They include drugs with favorable pharmacokinetics that allow …
Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1
H Zhang, Y Zhou, C Alcock, T Kiefer, D Monie… - Journal of …, 2004 - Am Soc Microbiol
Human immunodeficiency virus type 1 (HIV-1)-infected individuals who develop drug-
resistant virus during antiretroviral therapy may derive benefit from continued treatment for …
resistant virus during antiretroviral therapy may derive benefit from continued treatment for …
The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART
F Van Leth, S Andrews, B Grinsztejn, E Wilkins… - Aids, 2005 - journals.lww.com
Methods: A post-hoc analysis within the randomized controlled 2NN trial comparing efficacy
between regimes containing nevirapine (NVP), efavirenz (EFV), or both, in addition to …
between regimes containing nevirapine (NVP), efavirenz (EFV), or both, in addition to …
[HTML][HTML] Albumin nanoparticles coated with polysorbate 80 as a novel drug carrier for the delivery of antiretroviral drug—Efavirenz
Materials and Methods: Nanoparticles were prepared by desolvation technique and coated
with polysorbate 80. Ethanol, glutaraldehyde, and mannitol were used as desolvating, cross …
with polysorbate 80. Ethanol, glutaraldehyde, and mannitol were used as desolvating, cross …
Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa®), in antiretroviral-naïve patients: A …
BACKGROUND: Although efavirenz and lopinavir/ritonavir (r) are both recommended
antiretroviral agents in antiretroviral-naïve HIV-infected patients, there are few randomized …
antiretroviral agents in antiretroviral-naïve HIV-infected patients, there are few randomized …
Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor–based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients …
Objective: To compare the clinical, immunologic, and virologic outcomes of efavirenz (EFV)-
based versus protease inhibitor (PI)–based highly active antiretroviral therapy (HAART) in …
based versus protease inhibitor (PI)–based highly active antiretroviral therapy (HAART) in …
Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1–Infected Patients Starting Efavirenz, Lopinavir–Ritonavir, or Atazanavir–Ritonavir …
JM Miro, C Manzardo, E Ferrer, M Loncà… - JAIDS Journal of …, 2015 - journals.lww.com
Background: Few randomized clinical trials have investigated antiretroviral regimens in very
advanced HIV-1–infected patients. The objective was to study the immune reconstitution in …
advanced HIV-1–infected patients. The objective was to study the immune reconstitution in …
Efavirenz for HIV-1 infection in adults: an overview
C Fortin, V Joly - Expert Review of Anti-infective Therapy, 2004 - Taylor & Francis
Efavirenz (Sustiva®, Bristol–Myers Squibb) is a non-nucleoside reverse transcriptase
inhibitor that has been used successfully since the late 1990s to treat HIV-1 infection, and …
inhibitor that has been used successfully since the late 1990s to treat HIV-1 infection, and …
[PDF][PDF] Simplification of antiretroviral treatment: how to sustain success, reduce toxicity and ensure adherence avoiding PI use
P Barreiro, T García-Benayas, V Soriano, J Gallant - AIDS rev, 2002 - researchgate.net
Shortly after protease inhibitors (PI) began to be widely prescribed for the treatment of HIV
infection in 1996, we learned that the virological efficacy of highly active antiretroviral …
infection in 1996, we learned that the virological efficacy of highly active antiretroviral …